Concepedia

William B. Ainsworth

WB

4

Publications

373

Citations

4

H-Index

2018

Active since

Affiliations

AbbVie (United States)(Current)

The University of Texas MD Anderson Cancer Center

University of Chicago

William B. Ainsworth is an author at AbbVie (United States) specializing in tumor immunity, pharmacotherapy, and immunology.

Top concepts

Publications per year

2018–2023

4

Publications

4

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

Todd A. Hopkins, William B. Ainsworth, Paul A. Ellis et al. · Molecular Cancer Research · 2018 · 250 citations

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, Daniel A. Pollyea, Jacqueline S. Garcia et al. · Blood · 2019 · 71 citations

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia

Farhad Ravandi, Asad Bashey, James M. Foran et al. · Blood Advances · 2023 · 36 citations · Full text

, , +14

Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

Keith W. Pratz, Courtney D. DiNardo, Dominik Selleslag et al. · Blood · 2020 · 16 citations

Rows per page

1–4 of 4